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cemic incident occurred with the onset of sepsis, while no 
apparent cause was identified for three hypoglycemic inci-
dents.  Conclusions: Our glucose protocol was effective, but 
hypoglycemia occurred more frequently than in older chil-
dren reported previously. Potential differences in glucose 
and insulin metabolism in term neonates appear to justify 
additional safety approaches, while awaiting further studies 
assessing the benefits of tight glucose protocols in this pop-
ulation. Meanwhile, we have decreased the initial insulin 
starting doses in our protocol. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 The acute stress response during critical illness causes 
hyperglycemia, which is associated with increased mor-
bidity and mortality in critically ill adults, children, and 
neonates  [1] . Although optimal glucose levels have not 
been established for any age group, it is becoming more 
evident that a worse outcome is independently associated 
with duration of hyperglycemia, peak glucose levels, in-
creased glucose variability, and occurrence of hypoglyce-
mia  [2] . A tight glucose regimen with insulin therapy im-
proved outcome in critically ill children  [3] , despite the 
occurrence of hypoglycemia [ ^  2.2 mmol  l –1 (40 mg  dl –1 )] 
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 Abstract 
 Background: A large single-center randomized trial showed 
that treating hyperglycemia in critically ill children improved 
outcome, despite an increased incidence of hypoglycemia, 
especially in infants.  Objectives: We evaluated the efficacy 
and incidence of hypoglycemia using a tight glucose proto-
col in critically ill term neonates.  Methods: Term hypergly-
cemic ( 1 8 mmol  l –1 ;  1 144 mg  dl –1 ) neonates treated with a 
tight glucose protocol during a 3.5-year period in a tertiary 
pediatric intensive care unit were retrospectively analyzed. 
 Results: Seventy-three term hyperglycemic neonates [age 0 
days (0–6), weight 3.2  8 0.8 kg, PRISM 16 (11–20)] were in-
cluded for analysis. Eighteen neonates died (25%). The initial 
mean (range) glucose level was 11.1 mmol  l –1 [9.6–15.2; 200 
mg  dl –1 (173–274)], and normoglycemia ( ! 8 mmol  l –1 ;  ! 144 
mg  dl –1 ) was reached within 5.3 h (1–25) with an overall treat-
ment duration of 27 h (10–57). Seven hypoglycemic inci-
dents (5 times  ^  2.2 mmol  l –1 ; 40 mg  dl –1 , and 2 times  ! 1.7 
mmol  l –1 ; 31 mg  dl –1 ) occurred in 5 (6.7%) infants, without 
severe clinical signs. Three hypoglycemic incidents were di-
rectly explained due to a protocol violation. One hypogly-
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and severe hypoglycemia [ ^  1.7 mmol  l –1 (31 mg  dl –1 )] in 
25 and 5% of the children, predominantly ( 1 80%) in in-
fants  [3] . A study with very low birth weight neonates 
with early insulin therapy showed an increased incidence 
of hypoglycemia (29 vs. 17%) and parenchymal abnor-
malities detected with cranial ultrasound in those treated 
with insulin, and was discontinued early on the grounds 
of futility  [4] .
 Young age has long been recognized as a risk factor for 
developing hypoglycemia  [5] . Furthermore, although du-
ration and degree of hypoglycemia are important vari-
ables that have not been elucidated, the developing brain 
is susceptible to hypoglycemia and it may result in per-
manent damage  [6, 7] .
 Glucose control protocols designed to maintain nor-
moglycemia while minimizing glucose variability and 
hypoglycemic incidents are therefore of the essence in 
this population. Simple model-based computer-assisted 
or nurse-driven protocols have been reported in critical-
ly ill adults  [8, 9] and children  [10–12] . To date, no studies 
have shown feasibility and safety of these protocols spe-
cifically in critically ill newborn infants. Therefore, we 
evaluated the efficacy (time to achieve normoglycemia, 
duration of therapy) and safety (hypoglycemic incidents, 
protocol violations) of a tight glucose protocol in hyper-
glycemic term neonates less than 28 days old.
 Patients and Methods 
 Patients 
 The Pediatric Intensive Care Unit (PICU) at Erasmus MC – 
Sophia Children’s Hospital, Rotterdam, The Netherlands, is a 34-
bed mixed ICU. Term neonates less than 28 days old, admitted to 
our PICU from January 2006 to September 2009, and treated with 
our tight glucose protocol were retrospectively evaluated.
 Insulin Protocol 
 Term neonates received glucose according to our protocol 
(4–6 mg  kg –1  min –1 ) and were treated with a step-wise nurse-
driven glucose control protocol which was published previously 
 [12] . Briefly, neonates with sepsis, multiple organ failure, and/or 
receiving mechanical ventilation were treated after two consecu-
tive blood glucose levels of  1 8 mmol  l –1 ( 1 145 mg  dl –1 ) within 
1 h. Depending on the blood glucose level at the start of treatment, 
insulin was started at a dose ranging from 20 to 50 mIU  kg –1  h –1 . 
Thereafter, the nurse was allowed to adjust the insulin rate ac-
cording to the nurse-driven step-wise protocol up to a rate of 200 
mIU  kg –1  h –1 , after which the attending physician needed to be 
consulted. Blood glucose levels were checked hourly until the tar-
get range [4–8 mmol  l –1 (72–145 mg  dl –1 )] was achieved for three 
consecutive measurements, after which measurements were per-
formed every 3 h. Insulin therapy was stopped at any time accord-
ing to clearly defined criteria in the protocol ( fig. 1 )  [12] .
 Blood Glucose Analysis and Definitions 
 Blood glucose measurements were obtained by the nurses as 
soon as possible after admission from indwelling arterial cathe-
ters or from a capillary puncture, and measured on a blood gas 
analyzer (ABL 625; Radiometer, Copenhagen, Denmark) or a 
point-of-care bedside system (HemoCue AB, Sweden).
 Normoglycemia was defined as blood glucose levels between 
4 and 8 mmol  l –1 (72–145 mg  dl –1 ). Time to reach normoglycemia 
was defined as the time from start of insulin therapy until the first 
blood glucose level  ! 8 mmol  l –1 ( ! 145 mg  dl –1 ). Hypoglycemia 
was defined as blood glucose  ^  2.2 mmol  l –1 ( ^  40 mg  dl –1 ). Se-
vere hypoglycemia was defined as blood glucose  ! 1.7 mmol  l –1 
( ! 31 mg  dl –1 )  [3] . Signs of hypoglycemia were defined as mild 
(sweating, agitation, lethargy), severe [hemodynamic deteriora-
tion, neurological deteriorations (convulsions, coma)] or death. 
Measurements showing blood glucose levels  ! 2.6 mmol  l –1 (47 
mg  dl –1 ) or  1 15 mmol  l –1 (272 mg  dl –1 ) were repeated immedi-
ately on the blood gas analyzer. Neonates with blood glucose lev-
els  ! 2.6 (47 mg  dl –1 ) were given a bolus of dextrose 10% 5 ml  kg –1 
over 10 min.
 Data Collection 
 Patients were assessed by the Pediatric Risk of Mortality 
(PRISM) score  [13] , which is a validated measure of the severity 
of multiple organ dysfunction in PICUs. Hypoglycemic inci-
dents were recorded and analyzed for protocol violations. Based 
on our previous evaluation of the glucose protocol in children 
 [12] , we focused on two types of protocol violations (incorrect 
insulin starting dose, inadequate insulin adjustment/discontin-
uation).
 Statistical Analysis 
 Data are presented as medians with interquartile ranges, un-
less otherwise specified. Statistical significance was considered at 
p  !  0.05. Comparisons between neonates with and without hypo-
glycemia were made with the Mann-Whitney U test. Data were 
analyzed using a standard analysis software program (SPSS ver-
sion 17.0 for Windows, SPSS, Chicago, Ill., USA). The study was 
approved by the Medical Ethics Committee of Erasmus Medical 
Center, and was registered in the Dutch trial register (www.trial-
register.nl. registration number NTR2400).
 Results 
 Patients 
 In the 44-month period, 4,919 children were admit-
ted to our PICU, of whom 383 children (7.8%; age 4.9 
year; 0–18) were treated for hyperglycemia. In total, 799 
(16.2%) were neonates less than 28 days old, of whom 73 
[9.1%; age 0 days (0–6), weight 3.2  8 0.8 kg] were treat-
ed with the nurse-driven glucose control protocol. Their 
characteristics are shown in  table 1 . Overall mortality 
was high (25%) in the hyperglycemic neonates diag-
nosed with various medical and surgical diagnoses ( ta-
ble 2 ).
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Two subsequent (1 h pause)
measurements of blood glucose
>8 mmol • l–1 (>145 mg • dl–1)
with a glucose intake: 4–6 mg/kg/min
After start or adjustment of insulin infusion:
Check glucose hourly until 3 times within target range 4–8 mmol • l–1
(72–145 mg • dl–1), after which glucose should be checked every 3 h
Glucose
>8–11 mmol • l–1 (145–200 mg • dl–1)
>11–15 mmol • l–1 (200–272 mg • dl–1)
>15–20 mmol • l–1 (272–364 mg • dl–1)
>20 mmol • l–1 (364 mg • dl–1)
Glucose <4 mmol • l–1 
(72 mg • dl–1)
Check glucose every 30 min until 
glucose >4 mmol • l–1 (72 mg • dl–1)
Stop criteria:
-blood glucose <4 mmol • l–1 (72 mg • dl–1)
-insulin rate <15 mIU• kg–1 • h–1 at any time
-insulin rate <30 mIU• kg–1 • h–1 during 24 h
-start enteral bolus feeding
-interruption of continuous feeding or glucose infusion
-discharge from PICU
Insulin >200 mIU• kg–1 • h–1 t consult
physician (max. dose = 600 mIU• kg–1 • h–1)
Glucose >50% 
decrease
Glucose >25% 
decrease
Glucose increase or
≤25% decrease
-Stop insulin
-Glucose <2.6 mmol • l–1
(47 mg• dl–1): 
Bolus glucose 10%
5 ml • kg–1 in 10 min   
Decrease
insulin dose
by 50%
Insulin
t 20
t 30
t 40
t 50
Insulin initial dose (mIU • kg–1 • h–1)
Glucose
4–8 mmol • l–1 
>8–11 mmol • l–1 
>11 mmol • l–1 
Insulin
t 1/2
t 2/3
t sqa
Glucose 
mmol • l–1
4–6 
>6–8
>8–11
>11–15
>15–20
>20
Insulin
mIU • kg–1• h–1
t –50%
t sqa
t +10
t +20
t +30
t +40
 Fig. 1. Original and evaluated step-wise 
nurse-driven glucose control protocol for 
neonates less than 28 days old.  
Table 1.  Characteristics of neonates (0–28 days) treated according to glucose control protocol
Normoglycemic
(n = 68)
Hypoglycemic
(n = 5)
All neonates
(n = 73)
p 
value
Male:female 40:28 2:3 42:31 0.41
Age on admission to PICU, days 0 (0–5) 1 (0–21) 0 (0–6) 0.38
Mean weight 8 SD, kg 3.280.8 3.080.5 3.280.8 0.31
PRISM III 15 (12–22) 10 (5–12) 14 (11–20) 0.02
Glucocorticoids, n 40 (59%) 2 (40%) 42 (58%) 0.41
Mean glucose intake 8 SD, mgkg–1min–1 4.782.4 5.081.1 4.782.3 0.37
Time to start insulin infusion after first hyperglycemic incident, h 5.8 (2.5–11) 9.3 (2.3–25.4) 5.8 (2.5–11.0) 0.53
Time to achieve normoglycemia, h 5.3 (2.6–8.0) 6.1 (3.7–10.1) 5.3 (2.7–8.5) 0.40
Length of stay, days 15.5 (6.3–29.3) 7.0 (4.5–30.0) 15.0 (6.5–29.5) 0.54
Glucose level at start of insulin therapy, mmoll–1 11.2 (9.6–15.4) 10.8 (9.6–11.7) 11.1 (9.6–15.2) 0.49
Initial insulin dose, mIUkg–1h–1 20 (20–30) 20 (15–20) 20 (20–30) 0.13
Maximum insulin dose, mIUkg–1h–1 50 (30–88) 60 (45–75) 0 (30–80) 0.49
Duration of insulin therapy, h 26 (10–56) 33 (13–33) 27 (10–57) 0.37
Mortality, n 17 (27%) 1 (20%) 18 (25%) 0.75
V alues are medians with IQR in parentheses, unless otherwise depicted; p values for normoglycemic vs. hypoglycemic neonates.
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 Intake 
 Overall glucose intake was 4.7  8 2.3 mg  kg –1  min –1 
and not different in the neonates who developed hypogly-
cemia ( table 1 ). At start of the insulin therapy, 5 neonates 
received full continuous enteral feeding, 37 received full 
parenteral nutrition with amino acids (Primene; Baxter 
Inc., Utrecht, The Netherlands) and lipids (Intralipid; 
Fresenius Kabi Inc., Utrecht, The Netherlands), and 4 
were receiving combined (par)enteral nutrition. Thirty-
three patients received no nutrients other than parenter-
al glucose.
 Glucose Control Protocol 
 Insulin treatment was initiated 5.8 h (1–38) after the 
first episode of hyperglycemia [12.5  8 4.1 mmol  l –1 (225 
 8 74 mg  dl –1 )]. The initial insulin starting dose was 20 
mIU  kg –1  h –1 (10–100), the maximum dose reached was 
50 mIU  kg –1  h –1 (20–450). We recorded a total of 196 pa-
tient days of insulin therapy, of whom 79.1% had daily 
blood glucose levels of  ! 8.0 mmol  l –1 ( ! 144 mg  dl –1 ) 
( fig. 2 ). Normoglycemia was reached within 12 h of initi-
ating insulin therapy in 65 neonates (90.3%), and the me-
dian time to reach normoglycemia was 5.3 h (1–25). One 
infant died before reaching the glucose target range. The 
overall duration of insulin therapy was 27 h (1–308), while 
50 (68.5%) of the neonates were treated less than 48 h
 and only 12 (15.1%) neonates received insulin for  1 72 h.
 Hypoglycemic Incidents and Protocol Violations 
 Episodes of moderate hypoglycemia occurred in 3 
(4.1%) neonates and severe hypoglycemia occurred in 2 
(2.7%) neonates, without any severe clinical signs. Four 
neonates were recorded as being pale and lethargic. The 
intervention with a bolus of glucose after insulin infusion 
was stopped was sufficient to treat the hypoglycemic in-
cidents. One (20%) hypoglycemic infant died several days 
later due to portal vein thrombosis and acute liver failure 
after a Kasai procedure for biliary atresia. In the group 
who did not develop hypoglycemia, 17 (27%) neonates 
died. Blood glucose levels, age, glucocorticoid therapy, 
and clinical diagnoses at initiation of insulin therapy, 
dose and duration of insulin therapy, and time to achieve 
normoglycemia did not differ between hypoglycemic and 
non-hypoglycemic neonates ( table 1 ). Hypoglycemia oc-
curred twice in the 2 neonates with severe hypoglycemia, 
although severe hypoglycemia occurred no more than 
once in these neonates. Thus, a total of 5 hypoglycemic 
and 2 severe hypoglycemic incidents were recorded. The 
hypoglycemic incidents occurred at day 2 (1–5) of admis-
sion at the age of 4 days (1–30), 8 h (2–13) after initiation 
of insulin therapy.
Table 2. Diagnoses of neonates treated according to glucose con-
trol protocol 
n
Surgical
Non-ECMO
Congenital diaphragmatic hernia 18
Congenital heart defect 7
Congenital abdominal malformation 10
Congenital pulmonary malformation 2
(Post-)Necrotizing enterocolitis 1
ECMO
Congenital diaphragmatic hernia 9
Meconium aspiration 8
Persistent pulmonary hypertension 5
Congenital heart defect 1
Medical
Infection
Viral bronchiolitis 3
Meningitis 1
Sepsis 1
Meconium aspiration 1
Persistent pulmonary hypertension 3
Other 3
 ECMO = Extracorporeal membrane oxygenation.
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 Fig. 2. Efficacy of the tight glucose control protocol in neonates 
treated with insulin showing the highest blood glucose readings 
in mmol  l –1 (mg  dl –1 ) per day after start of the insulin therapy in 
percentage of patient days. 
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 Of these 7 hypoglycemic incidents, no apparent cause 
could be identified in three incidents. In retrospect, 1 hy-
poglycemic infant was diagnosed with sepsis within sev-
eral hours after the hypoglycemic incident. Three proto-
col violations were identified which could have been re-
sponsible for the (severe) hypoglycemic incidents. In 2 
neonates, insulin was decreased too late or not at all after 
plasma glucose levels dropped, whereas in 1 infant insu-
lin was not discontinued according to the protocol.
 In the 73 neonates receiving insulin, 31 protocol viola-
tions were identified at the initiation of insulin therapy, 
which were not associated with the hypoglycemic inci-
dents. The starting dose of insulin was below protocol 
recommendations in 26 (34.7%) neonates and above pro-
tocol recommendations in 3 (4%) neonates. In 2 patients, 
the start of insulin should have been cancelled as the 
blood glucose was  ! 8 mmol  l –1 immediately prior to the 
start of the insulin treatment.
 Discussion 
 This is the first evaluation of the efficacy and safety of 
a tight glucose protocol specifically in critically ill term 
neonates. Consistent with previous evaluations of tight 
glucose protocols in older children  [10–12] , we showed 
that our nurse-driven glucose control protocol achieved 
normoglycemia within 5.3 h and in 90% of the neonates 
within 12 h and 79.1% of daily blood glucose levels of  ! 8.0 
mmol  l –1 ( ! 144 mg  dl –1 ). Remarkably, the target ranges 
were achieved while a large proportion (34.7%) of the in-
sulin starting doses were below protocol recommenda-
tion. Furthermore, overall treatment duration was short, 
 and it is not clear whether these neonates could have ben-
efited from the tight glucose regimen.
 While hyperglycemia is associated with a poor out-
come in neonates  [14–16] , outcome studies of tight glu-
cose protocols have not focused specifically on this pop-
ulation. Additionally, no mechanistic studies have ex-
plored the effects of hyperglycemia or insulin therapy in 
neonates. The principal cause of cellular and organ sys-
tem failure in critical illness hyperglycemia is glucose 
overload resulting in excessive generation of oxygen rad-
icals, which leads to mitochondrial dysfunction, in-
creased generation of inflammatory cytokines, and dis-
turbed energy metabolism  [17] . Insulin therapy has been 
shown to protect the function and structure of the mito-
chondrial compartment in adults and children  [18, 19] . It 
is not likely that there will be substantial differences in 
the mechanistic effects of hyperglycemia or insulin ther-
apy on the glucose toxicity in infants. Therefore, despite 
the lack of beneficial results in outcome studies, potential 
benefits of insulin therapy in the infant population should 
not be ignored.
 However, we recognize the 7 (severe) hypoglycemic 
incidents in 5 neonates (6.7%). Using a treatment algo-
rithm in critically ill older children (by us and others), 
the reported incidence of hypoglycemia was 0–4%  [10–
12] . As the timeframe of the evaluation was similar for 
the older children without any hypoglycemic incidents 
 [12] as for the infants in the present study, neither the 
protocol implementation, nor the experience working 
with the protocol by nursing staff and physicians, ex-
plains this difference. So, it appears that neonates are 
more susceptible to hypoglycemia following insulin ad-
ministration.
 Although three hypoglycemic incidents were ex-
plained by protocol violations, three hypoglycemic inci-
dents occurred without apparent cause and one occurred 
in the onset of sepsis. Furthermore, in 2 neonates, hypo-
glycemia occurred twice. These observations allow us 
to speculate that neonates indeed are a specific and vul-
nerable age group in the PICU. Possibly the etiology in 
these neonates is different from the ‘regular’ insulin-re-
sistance-induced critical illness hyperglycemia. For in-
stance, in the pediatric population the initial phase of 
sepsis can cause insulin deficiency, rather than resis-
tance  [20] . Additionally, high parenteral glucose intake 
can, independent of insulin resistance, produce hyper-
glycemia. Under such circumstances, insulin infusion 
would decrease plasma glucose levels faster than under 
insulin resistant conditions. Furthermore, neonates lack 
the precise control of glucose homeostasis as they un-
dergo major changes in glucose and insulin metabolism. 
Glycogen stores are low and glucose homeostasis pri-
marily depends on gluconeogenesis, partially explaining 
why young age itself is a risk factor for developing hypo-
glycemia  [5] . Furthermore, a transformation in   -cell 
population, due to a transient wave of apoptosis and re-
population, causes a wide variation of insulin secretory 
capacities in newborn neonates  [21] . Moreover, hyperin-
sulinemic euglycemic clamp studies have shown that 
infants have greater peripheral glucose utilization  [22] 
than older children  [23] . Insulin receptors in infants are 
higher in number as well as affinity, partially explaining 
this increased sensitivity  [24] . Additionally, it has recent-
ly been shown that there exists a developmental change 
in peripheral insulin signaling  [25] . Although reduced 
contents of glucose transporters (GLUT) 1 and 4 were 
found, the proximal insulin signaling proteins (IR-  , 
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IRS-1 and Akt) were increased in muscle of neonatal ba-
boons  [25] . These wide variations in the ability of glucose 
production, insulin secretory capacity, and insulin sen-
sitivity might at least partially explain the differences 
from older children and adults. Furthermore, it has been 
shown that   -cell dysfunction instead of, or in addition 
to, insulin resistance might play a major role in hyper-
glycemia during pediatric critical illness  [20] . Whether 
this is also true in neonates is unknown. This suggests 
that when insulin therapy is considered in critically ill 
neonates, increased awareness is needed. With the re-
sults of the present study, we have adjusted the proto-
col on our PICU for infants less than 28 days old, such 
that the initial insulin starting doses decreased by 10 
mIU  kg –1  h –1 and the minimum insulin dose as stop cri-
teria ( fig. 3 ).
 Our study has limitations. It is an observational study. 
It adds insight to the safety and effectivity of tight glucose 
protocols for critically ill neonates, but it was not de-
signed to show whether outcome improved with our tight 
glucose protocol. We further acknowledge that our glu-
cose target range was higher than that of Vlasselaers et al. 
 [3] , which could at least partially explain the difference 
in hypoglycemic incidents. However, as the ideal target 
range of tight glucose regimens still needs to be estab-
lished, less strict protocols might be sensible.
 We conclude that neonates can be treated with a nurse-
driven glucose protocol, as target ranges were met, and 
overall treatment was short. However, hypoglycemia oc-
curred more frequently in neonates than in older chil-
dren, alerting us that this is a vulnerable population 
where additional safety approaches are warranted. Fu-
Two subsequent (1 h pause)
measurements of blood glucose
>8 mmol • l–1 (>145 mg • dl–1)
with a glucose intake: 4–6 mg/kg/min
After start or adjustment of insulin infusion:
Check glucose hourly until 3 times within target range 4–8 mmol • l–1
(72–145 mg • dl–1), after which glucose should be checked every 3 h
Glucose
>8–11 mmol • l–1 (145–200 mg • dl–1)
>11–15 mmol • l–1 (200–272 mg • dl–1)
>15–20 mmol • l–1 (272–364 mg • dl–1)
>20 mmol • l–1 (364 mg • dl–1)
Glucose >4 mmol • l–1 
(72 mg • dl–1)
Check glucose every 30 min until 
glucose >4 mmol • l–1 (72 mg • dl–1)
Stop criteria:
-blood glucose <4 mmol • l–1 (72 mg • dl–1)
-insulin rate <5 mIU• kg–1 • h–1 at any time
-insulin rate <20 mIU• kg–1 • h–1 during 24 h
-start enteral bolus feeding
-interruption of continuous feeding or glucose infusion
-discharge from PICU
Insulin >200 mlU• kg–1 • h–1 t consult
physician (max. dose = 600 mlU• kg–1 • h–1)
Glucose >50% 
decrease
Glucose >25% 
decrease
Glucose increase or
≤25% decrease
-Stop insulin
-Glucose <2.6 mmol • l–1
(47 mg• dl–1): 
Bolus glucose 10%
2 ml • kg–1 in 10 min   
Decrease
insulin dose
by 50%
Insulin
t 10
t 20
t 30
t 40
Insulin initial dose (mIU • kg–1 • h–1)
Glucose
4–8 mmol • l–1 
>8–11 mmol • l–1 
>11 mmol • l–1 
Insulin
t 1/2
t 2/3
t sqa
Glucose 
mmol • l–1
4–6 
>6–8
>8–11
>11–15
>15–20
>20
Insulin
mIU • kg–1• h–1
t –50%
t sqa
t +10
t +20
t +30
t +40
sqa
 Fig. 3. Adjusted step-wise nurse-driven 
glucose control protocol for neonates less 
than 28 days old, based on the present 
study.  
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ture studies assessing the outcome of a tight glucose reg-
imen in the infant population, and addressing approach-
es which will help prevent hypoglycemia, are of utmost 
importance. It should be emphasized that currently no 
evidence of the beneficial effect insulin therapy in neo-
nates exists, and that insulin is a drug with potential seri-
ous side effects that should be used with care. Meanwhile, 
we will evaluate our adjusted protocol ( fig. 3 ) and engage 
in a long-term follow-up of the neonates.
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